Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — April 2020

Planlagt Fastgjort Låst Flyttet Genmab
943 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • E Offline
    E Offline
    E_L
    wrote on sidst redigeret af
    #905

    i can find GBP65 mio in Cash proceeds related to ofatumumab milestone in the GSK presentation. Can Genmab expect any milestones?

    1 Reply Last reply
    0
    • E Offline
      E Offline
      E_L
      wrote on sidst redigeret af
      #906

      (they got that from Novartis)

      1 Reply Last reply
      0
      • G Offline
        G Offline
        GeorgeBest
        wrote on sidst redigeret af
        #907

        don't think, Jan van de Winkel gave up on one time milestones when he renegotiated the Arzerra deal

        1 Reply Last reply
        0
        • G Offline
          G Offline
          GeorgeBest
          wrote on sidst redigeret af
          #908

          Genmab thereby got rid of participating in developement cost

          1 Reply Last reply
          0
          • G Offline
            G Offline
            GeorgeBest
            wrote on sidst redigeret af
            #909

            it was in 2011 or so, when Genmab were in a very bad standing financially

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #910

              thanks. good memory 😉

              1 Reply Last reply
              0
              • BulderB Offline
                BulderB Offline
                Bulder
                wrote on sidst redigeret af
                #911

                Det er gået under min radar, at Janssen kører kombi-studier i dara-talquetamab og dara-teclistamab i MM. Men betryggende at der holdes gang i dara-gryden. (Der er jo også hexa-cd38.) Når nu konkurrenter trænger sig på - Tak-079 og bela-m.

                1 Reply Last reply
                0
                • S Offline
                  S Offline
                  Sukkeralf
                  wrote on sidst redigeret af
                  #912

                  Agree with GB on milestones for ofa i MS

                  1 Reply Last reply
                  0
                  • SolsenS Offline
                    SolsenS Offline
                    Solsen
                    wrote on sidst redigeret af
                    #913

                    Jeg håber og tror på at de kombinationer de afprøver er gode. Mener at have set meget opmuntrene data fra dara og bcmaxcd3 kombinationen. Hvor jeg tænkte, at daras markedspotentiale kunne være truet fordi dara kun var med i indledende behandling. Men alt det ligger noget ud i fremtiden.

                    1 Reply Last reply
                    0
                    • SolsenS Offline
                      SolsenS Offline
                      Solsen
                      wrote on sidst redigeret af
                      #914

                      https://clincancerres.aacrjournals.org/content/clincanres/early/2020/03/23/1078-0432.CCR-19-2299.full.pdf Nu husker jeg ikke om denne er lagt op tidligere. Men her er synergien mellem dara og BCMAxCD3 beskrevet.

                      1 Reply Last reply
                      0
                      • BulderB Offline
                        BulderB Offline
                        Bulder
                        wrote on sidst redigeret af
                        #915

                        Tak solsen

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #916

                          so many articles on SC, just get it approved... https://www.reuters.com/article/multiple-myeloma-daratumumab/subcutaneous-daratumumab-effective-alternative-to-iv-formulation-for-multiple-myeloma-idUSL2N2BX1BJ

                          1 Reply Last reply
                          0
                          • D Offline
                            D Offline
                            DevOp
                            wrote on sidst redigeret af
                            #917

                            Everyone at the FDA is working on the Remdesivir approval 😉

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #918

                              i think Dara will probable save more lives over time then Remdesivir, so they are wrong 😉

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #919

                                but seriously, FDA apparantly not really delayed very
                                much, still approving some drugs rather fast

                                1 Reply Last reply
                                0
                                • D Offline
                                  D Offline
                                  DevOp
                                  wrote on sidst redigeret af
                                  #920

                                  Cross fingers for tomorrow or Friday next week

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #921

                                    Blood: A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis https://ashpublications.org/blood/article-abstract/135/18/1531/452572/A-prospective-phase-2-trial-of-daratumumab-in

                                    1 Reply Last reply
                                    0
                                    • E Offline
                                      E Offline
                                      E_L
                                      wrote on sidst redigeret af
                                      #922

                                      Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study https://ashpublications.org/blood/article-abstract/135/18/1541/440750/Safety-tolerability-and-response-rates-of

                                      1 Reply Last reply
                                      0
                                      • B Offline
                                        B Offline
                                        bibob
                                        wrote on sidst redigeret af
                                        #923

                                        I like this line. https://ashpublications.org/blood/article-abstract/135/18/1509/454455/AL-patients-don-t-dare-go-without-dara?redirectedFrom=fulltext 🙂

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #924

                                          😄 JNJ should use that in their marketing lol

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger